Next Treatments
Back to Eczema

vibozilimod

TypePill StagePhase 2 Latest updateDec 30, 2025Phase 2 results posted

What stands out

  • Immunomodulator
Derived from WHO name stem · This is a summary of public records for informational purposes only. It is not medical advice.

Results

Trial: SOLARES-AD-1
Clear or almost clear skinAfter 16 weeks
Placebo of SCD-044 Product61 people
7 in 100
SCD-044 Tablets of Low Dose (Dose 1)72 people
10 in 100
SCD-044 Tablets of Intermediate Dose (Dose 2)64 people
13 in 100
SCD-044 Tablets of High Dose (Dose 3)53 people
9 in 100
01020

SCD-044 Tablets of Low Dose (Dose 1) vs. placebo: p = 0.4564

SCD-044 Tablets of Intermediate Dose (Dose 2) vs. placebo: p = 0.2515

SCD-044 Tablets of High Dose (Dose 3) vs. placebo: p = 0.5055

Eczema score (EASI) at least 75% betterAfter 16 weeks
Placebo of SCD-044 Product61 people
10 in 100
SCD-044 Tablets of Low Dose (Dose 1)72 people
18 in 100
SCD-044 Tablets of Intermediate Dose (Dose 2)64 people
13 in 100
SCD-044 Tablets of High Dose (Dose 3)53 people
15 in 100
01020

SCD-044 Tablets of Low Dose (Dose 1) vs. placebo: p = 0.1966

SCD-044 Tablets of Intermediate Dose (Dose 2) vs. placebo: p = 0.5438

SCD-044 Tablets of High Dose (Dose 3) vs. placebo: p = 0.3713

NCT04684485 · Ages 18+ · Results posted Dec 2025 · This is a summary of trial data for informational purposes only. It is not medical advice.
What is IGA?
  • Based on morphological findings (overall appearance of the lesions at a given time point), scores will be assigned on a 5-point scale ('0' [clear] to 4 [severe]). The information presented represents the percentage of subjects, calculated as the proportion of subjects multiplied by 100.As this trial registered it · NCT04684485
What is EASI?
  • EASI stands for Eczema Area and Severity Index.
  • Based on gross morphological findings, scores will be assigned on a 4-point scale ['0' (absent), '1' (mild), '2' (moderate) and '3' (severe)] for each clinical sign. The information presented represents the percentage of subjects, calculated as the proportion of subjects multiplied by 100.As this trial registered it · NCT04684485
What does the p-value mean?

Clear or almost clear skin. If SCD-044 Tablets of Low Dose (Dose 1) did nothing, a gap this size would turn up by chance about 46 times in 100 (p = 0.4564), by the trial’s own test. If SCD-044 Tablets of Intermediate Dose (Dose 2) did nothing, a gap this size would turn up by chance about 25 times in 100 (p = 0.2515), by the trial’s own test. If SCD-044 Tablets of High Dose (Dose 3) did nothing, a gap this size would turn up by chance about 51 times in 100 (p = 0.5055), by the trial’s own test.

Eczema score (EASI) at least 75% better. If SCD-044 Tablets of Low Dose (Dose 1) did nothing, a gap this size would turn up by chance about 20 times in 100 (p = 0.1966), by the trial’s own test. If SCD-044 Tablets of Intermediate Dose (Dose 2) did nothing, a gap this size would turn up by chance about 54 times in 100 (p = 0.5438), by the trial’s own test. If SCD-044 Tablets of High Dose (Dose 3) did nothing, a gap this size would turn up by chance about 37 times in 100 (p = 0.3713), by the trial’s own test.

Why this trial?

vibozilimod has one trial with posted results, and SOLARES-AD-1 compared the drug with placebo on a result this page charts.

History

Earliest recorded event: Jul 30, 2021. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Dec 30, 2025Phase 2 results postedTo Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT04684485
  • Mar 18, 2025Phase 2 trial completedTo Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT04684485
  • Nov 11, 2024Phase 2 main data collectedTo Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT04684485
  • Jul 30, 2021Phase 2 trial startedTo Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT04684485

Sources

Trials